BioSpace News Archive

Prime Therapeutics LLC and Magellan Rx Management LLC released the 13th annual Medical Pharmacy Trend Report™, featuring a comprehensive view of provider-administered medical benefit drug trends, the largest driver of specialty drug spend.

SentiAR, Inc. a St. Louis, Missouri based pioneer in using Augmented Reality (AR) visualization technology for medical procedures has received their second FDA 510K clearance CommandEP™ adding a new integration.

Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs).

Zynex, Inc. (NASDAQ: ZYXI) will hold a conference call on Thursday, October 26, 2023 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2023.

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the publication of clinical data in Interventional Neuroradiology (INR) of the Zoom Aspiration Catheters in patients with large and medium vessel occlusions.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”) today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including Timeline for the company’s Phase 3 program in narcolepsy.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

MediLink Therapeutics (“MediLink”), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE.

HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson’s Disease in collaboration with NurrOn Pharmaceuticals.

QuidelOrtho Corporation today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu.